KEYNOTE-177 Cements Pembrolizumab as New Standard of Care in MSI-H/dMMR mCRC
Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.
Related Articles
Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Glofitamab Plus Chemotherapy Meets OS Primary End Point in Relapsed/Refractory DLBCL
Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups
Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.
Retrospective Study Highlights Evolving Community Use of BTK Inhibitors for CLL/SLL
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials
Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.
Current Treatment Options in Third-line MCL
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study
Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small…
Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Revisit Every OncLive On Air Episode from March 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.